Life Science Invest Fund (LSIF) to lead AcuCort AB 47,7 mio. SEK financing
AcuCort AB is in the commercialization phase after launching Zeqmelit® on September 1st, and AcuCort AB is following its business plan to now expand into bigger European markets and into the US.
As with all companies in our portfolio, LSIF has had an ongoing dialogue with AcuCort since our initial investment, and the dialogue has strengthened our decision to further support the company's expansion by taking on the leadership role in the relatively large right issue of SEK 47.7 million. LSIF subscribes for its pro rata share in the rights issue and is also the main guarantor. In total we have committed in excess SEK 10 million in the rights issue.
In this connection we are very pleased to note the investments from CEO Jonas Jönmark and Chairman of the Board Ebba Fåhraeus in this round underlining management confidence in the business case.
See press releases:
